Liquid biopsy is an advanced cancer technique for detecting that detects cancer using bio-fluids such as blood, cerebrospinal fluid (CSF), plasma, and urine. For cancer detection, this non-invasive diagnostic test uses circulating nucleic acids, circulating tumor cells (CTC), and exosomes as biomarkers.
Drivers of the Global Liquid Biopsy Market
Over the forecast period, rising cancer prevalence is a major driver driving growth in the worldwide liquid biopsy market. According to the World Health Organization, cancer caused around 18.1 million new cases and 9.6 million deaths globally in 2018.
Furthermore, growing funding for cancer R&D is projected to help the market grow. Cancer research funding by NCRI partners, for example, reached over US$ 750 million in 2018/19, according to the National Cancer Research Institute (NCRI).
Restraints in the Global Liquid Biopsy Market
Circulating free DNA (cfDNA) levels in serum and plasma differ. Such variations in cfDNA levels among patients may result in erroneous or unsatisfactory liquid biopsy test findings, limiting the global Liquid Biopsy Market growth.
Furthermore, the market's expansion is projected to be hampered by the high cost of liquid biopsy. The cost of equipment and reagents, as well as labor and professional expenditures, are all expenses related to liquid biopsy.
Opportunities in the Global Liquid Biopsy Market
The exact manipulation of fluid within sub-millimeter channels is the hallmark of microfluidics. Many studies for the development of lab-on-a-chip devices for biochemical investigations such cell separation, DNA and protein analysis, and PCR amplification are currently underway.
The Competitive Landscape of the Global Liquid Biopsy Market
Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Worldwide Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation are among the major companies in the global liquid biopsy market.
Key Developments in the Global Liquid Biopsy Market
To extend their product portfolio, major companies in the industry are focusing on collaboration methods. Saga Diagnostics, for example, struck agreements with Laboratoires Servier in January 2020 to perform a Liquid Biopsy Market on cancer patients involved in clinical studies.
Big market companies are similarly concentrating their efforts on presenting their products at major symposiums. For example, at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January 2020, GRAIL, Inc. presented new data from its liquid biopsy trial, CCGA, which failed to show a significant improvement in sensitivity when compared to data presented at the same symposium in 2019.
0 Comments